anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Oral microbial dysbiosis contributes to the development of schizophrenia (SZ). While numerous studies have investigated alterations in the oral bacterial microbiota among SZ patients, investigations into the fungal microbiota, another integral component of the oral microbiota, are scarce. In this cross-sectional study, we enrolled 118 Chinese patients with SZ and 97 age-matched healthy controls (HCs) to evaluate the oral fungal microbiota from tongue coating samples using internal transcribed spacer 1 amplicon sequencing and assess host immunity via multiplex immunoassays. Our findings revealed that SZ patients exhibited reduced fungal richness and significant differences in β-diversity compared to HCs. Within the oral fungal communities, we identified two distinct fungal clusters (mycotypes): Candida and Malassezia, with SZ patients showing increased Malassezia and decreased Candida levels. These key functional oral fungi may serve as potential diagnostic biomarkers for SZ. Furthermore, SZ patients displayed signs of immunological dysfunction, characterized by elevated levels of pro-inflammatory cytokines such as IL-6 and TNF-α, and chemokines including MIP-1α and MCP-1. Importantly, Malassezia mycotype correlated positively with peripheral pro-inflammatory cytokines, while Candida mycotype exhibited a negative correlation with these cytokines. In conclusion, we have demonstrated, for the first time, the presence of altered oral fungal communities and systemic immune dysfunction in Chinese SZ patients compared to HCs, providing novel insights into the potential role of oral fungi as biomarkers and the broader implications for understanding SZ pathogenesis.
This is a controlled feeding study in which the relative validity of stable carbon and nitrogen isotope ratio analysis as a biomarker of dietary intake is compared to controlled feedings and multiple 24-hour recalls. Participants will be randomly assigned to a sequence of diets to be fed on four occasions. Participants will undergo 24 hours of controlled feeding on four non-consecutive days over a month-long period. On the day after feeding, participants will complete 24-hour dietary recalls, and provide blood, hair, and fingernail samples for isotope ratio analyses. The investigators will use a crossover design and the diets will be either high or low in C4 plants (i.e., corn and cane products). A 24-hour urine collection will be done at home during each 24-hour feeding period. Participants will have height and weight measured at the screening visit. Weight will also be measured at each study visit. Additionally, data will be collected via questionnaires administered at each study visit.
FIELD: biotechnology, biochemistry. SUBSTANCE: invention relates to the improved method of large-scale production of thrombin-containing composition of therapeutic purity degree, an excellent safety and stability in storage. Method involves purification of crude thrombin treated with an antiviral composition by ion-exchange chromatography on a single column using sulfalkyl-activated polysaccharide, in part, sulfopropyl-Spherodex ®  as ion-exchange medium and increasing concentrations of phosphate buffer as an eluent. After isolation of thrombin from the final eluate phosphate buffer is replaced with stabilizing composition buffer and stabilized thrombin is subjected for an antiviral filtration and optional treatment by dry heat for the further inactivation of viruses. The end product has high specific activity. EFFECT: increased yield of the end product, high specific activity. 13 cl
PURPOSE:To provide a hair tonic containing an acetic acid ester of a fatty acid glyceride having a chain containing odd number of carbon atoms, having excellent absorbability and remarkably improved solubility and low-temperature stability and exhibiting excellent hair-growth promoting action. CONSTITUTION:The objective hair tonic contains 1.0-30.0wt.% of an acetic acid ester of a glyceride of a fatty acid having a chain containing odd number of carbon atoms (preferably 11-22C chain) (e.g. undecanoic acid or pentacosanoic acid). The above glyceride is e.g. monoglyceride of formula I or II (R is straight-chain organic group having a chain containing even number of carbon atoms), etc., or diglyceride of formula III or IV (R1 and R2 are organic chain group and at least one of the groups is straight-chain organic group having a chain containing even number of carbon atoms). The hair tonic has excellent hair-tonic effect and can be compounded with an adjutant and a drug- active component (e.g. vitamins, hormones, vasodilator, anti-inflammatory agent or cell-activation agent) in addition to the above essential component.
Data on the effects of PegIntron and ribavirin on growth come from an open-label study in subjects 3 through 17 years of age, in which weight and height changes were compared to US normative population data. In general, the weight and height gain of pediatric subjects treated with PegIntron and ribavirin lagged behind that predicted by normative population data for the entire length of treatment. Severely inhibited growth velocity (less than 3rd percentile) was observed in 70% of the subjects while on treatment. Following treatment, rebound growth and weight gain occurred in most subjects. Long-term follow-up data in pediatric subjects, however, indicates that PegIntron in combination therapy with ribavirin may induce a growth inhibition that results in reduced adult height in some patients [see Adverse Reactions (6.1)].

Similarly, an impact on growth was seen in subjects after treatment with ribavirin and INTRON A combination therapy for one year. In a long-term follow-up trial of a limited number of these subjects, combination therapy resulted in reduced final adult height in some subjects [see Adverse Reactions (6.1)].
Parkinson's disease (PD) is a disease caused by dopamine deficiency in the striatum resulting from the loss of dopaminergic neuronal cells in the cerebral substantia. It is a progressive neurodegenerative disease characterized by motor symptoms including gait disturbance and balance instability. In the early stages of Parkinson's disease, dysfunction of the sensorimotor area of the basal ganglia typically occurs, leading to habitual control hurdles. Accordingly, cognitive efforts are required to perform habitual tasks such as walking, and the automaticity of walking is reduced. Walking performance in a dual-task condition has been used to assess gait automaticity in patients with Parkinson's disease.

Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation method that can be used to change cortical activity. Recently, there has been growing attention on tDCS as an adjunct tool for rehabilitation. Several tDCS studies in patients with PD have reported the positive results of tDCS on motor function. However, few studies have reported the therapeutic effect of tDCS on the dual-task performance in PD. In addition, inconsistent results have been reported because tDCS protocol has been applied in various way. Therefore, this study aims to investigate an optimized stimulation site of tDCS that could improve the dual-task performance in patients with PD.
Doxorubicin is not an anti-microbial agent. Doxorubicin is emetigenic. Antiemetics may reduce nausea and vomiting; prophylactic use of antiemetics should be considered before administration of doxorubicin, particularly when given in conjunction with other emetigenic drugs. Doxorubicin should not be administered in combination with other cardiotoxic agents unless the patient's cardiac function is closely monitored. Patients receiving doxorubicin after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as trastuzumab, may also be at an increased risk of developing cardiotoxicity. Physicians should avoid doxorubicin-based therapy for up to 24 weeks after stopping trastuzumab when possible. If doxorubicin used before this time, careful monitoring of cardiac function is recommended (see WARNINGS, DOSAGE AND ADMINISTRATION).
A method for locating application records in an interactive-service database is described. The method features steps for creating multiple search tables which represent subsets of the database to be interrogated; for example the applications of an interactive service. In accord with the method, steps are provided for arranging the tables with keyword, record locators, indexed to record identifiers. Additionally, the method includes steps for providing each table with a unique coding and steps for generating table codes at the user reception system in response to a query for a database record entered with a variety of search strategies; as for example, character string searching approximating the record sought, alphabetized record searching, subject matter category searching and personalized record searching, among others. Further, the method includes steps for comparing the table code generated with available table codes for the database to select a table suited for the query. Thereafter, the appropriate table is presented at the reception system so the table keywords can be reviewed and a desired record selected and presented.
Eligible patients will be randomly assigned into one of two treatment groups using a randomization table generated by a computer. The test group (10 sinuses) will receive Osteocel Plus and control group (10 sinuses) will receive conventional cortical-cancellous particulate allograft material. The objective of this research is to serve as a pilot study, gathering information that will guide the design of a larger subsequent study. Little is known about the distribution of bone quality changes in patients who receive Osteocel Plus graft to augment the maxillary sinus. Ten subjects per group is reasonable for a pilot study, providing an 89% probability of estimating the true mean for bone quality and implant stability to within half a standard deviation in each group. These means, along with the observed standard deviations and within-subject correlations that the investigators obtain will prove essential for designing the larger, confirmatory study that constitute the next phase of this research.

A clinical radiographic/surgical guide will be fabricated for each patient to be used for CBCT scan prior to sinus augmentation procedure. The same clinical radiographic/surgical guide will be used for CBCT scan prior to the implant placement to measure the amount of bone regeneration following four months of healing at the exact sites. One line will measure the horizontal width and the other line will measure the vertical height. The horizontal width will be measured at a vertical height of 10 mm from the sinus floor in the sinus cavity based on the conventional average length of dental implant used in implant dentistry. The difference in the measurements for all surgical sites after the grafting procedure and before the implant placement will provide a clinical assessment of the amount of bone regeneration.

Forty trephined core samples will be retrieved surgically from two areas of the grafted lateral window at the time of implant placement. One core sample will be retrieved from the anterior area, approximately 4 mm distal to the anterior tack which was used to fix the resorbable membrane, and the other one will be retrieved from the posterior area, approximately 4 mm mesial of the posterior tack which was used to fix the resorbable membrane. Histomorphometric analysis will be performed on three fields for each section using specialized software. Volume of vital bone, graft remnants, and connective tissue will be measured based on the averages of the percentages at a magnification of 63X. Data will be statistically analyzed using Statistical Package for the Social Sciences (SPSS 13.0 for Windows software) program to compare between test and control groups.
The study is being conducted from Jan 2016 to Dec 2020 with 20 cooperation units. It consists of 2 sets. The registry set is designed as a prospective real-world registry. The trial set is designed as a prospective pragmatic clinical trial, specifically for the patients with perforating arterial feeders. The two sets share a common grouping: the traditional operation group and the one-staged hybrid operation group. The assignment is based on the clinical condition in the registry set and is randomized in the trial set. End points will be evaluated at scheduled time points. The safety and efficiency of one-staged hybrid operation in treating complex bAVMs will be validated.
Participants will receive approximately 0.9 mg/kg deflazacort once daily orally for 52 weeks in Period 1 and for 52 weeks in Period 2. The target dose could be varied +/- 20 percent (%) depending upon the available tablet strengths and change in participant's weight.
SAD cohorts 1-5. Randomised participants in each cohort will receive a single IV dose of APB-R3.
The invention provides an oral liquid for eliminating addiction. The oral liquid is prepared from 8.5g to 28.5g of semen coicis, 8.5g to 28.5g of angelica sinensis, 5.5g to 21.1g of salvia miltiorrhiza, 2.5g to 14.4g of radix curcumae, 5.2g to 15.2g of cyperus rotundus, 3.5g to 10.5g of frankincense, 2.5g to 10.5g of myrrh, 5.5g to 20.5g of radix paeoniae rubra, 0.5g to 5.5g of borneol, 0.5g to 13.5g of scorpion and 5.5g to 20.5g of trichosanthes kirilowii maxim. The invention further discloses a preparation method of the oral liquid for eliminating addiction. The oral liquid is simple to prepare and suitable to popularize. The oral liquid is developed by aiming at the pathogenesis of addiction via combination of syndrome differentiation of the traditional medicine in China and an advanced extraction method of the modern medicine, and is a Chinese herbal medicine compound preparation applied to mastitis and hyperplasia of mammary glands. The oral liquid cannot generate side effects and can be used for obviously relieving clinical symptoms of the mastitis and hyperplasia of mammary glands, and is superior to the existing various formulas.
A preparation for taking dental impressions and to be prepared for use by mixing it with water, comprises a colloid, a metal salt, and alkaline component which when the preparation is mixed with water renders the preparation alkaline so that the metal salt is initially substantially insoluble in the water and incapable of reacting with the colloid, and a slow acting acidifying component which causes the alkaline preparation to assume a neutral or slightly acid pH value so that the metal salt dissolves in the water and reacts with the colloid to form a resilient gel, the acidifying component being in stoichiometric excess with respect to the alkaline component.  The metal salt may be a carbonate or silicate of lead, barium, strontium or calcium.  The colloid may be a water soluble alginate, pectate or salt of carboxymethyl-cellulose.  The acidifying component may be a weak acid (acetic acid), a salt derived from a weak base and a strong acid, an organic or inorganic ester, an organic or inorganic acid anhydride (molybdic or tungstic acid anhydride), a silicofluoride, a titanofluoride or a zirconofluoride.  The alkaline component may be sodium hydroxide or alkali metal silicate, aluminate or zincate.  The preparation may include colour change indicators e.g. phenolphthalein and thymolphthalein.  In the examples the preparations comprise (1) diatomaceous earth, lead silicate, sodium alginate, sodium silicofluoride and sodium hydroxide; (2) diatomaceous earth, lead silicate, sodium alginate, sodium silicate and sodium silicofluoride; (3) diatomaceous earth, barium carbonate, sodium alginate, sodium carbonate, sodium silicate and sodium silicofluoride; (4) diatomaceous earth, sodium alginate, lead silicate, sodium silicate, sodium silicofluoride, potassium silicofluoride, thymolphthalein and phenolphthalein.
An anti-aging cosmetic composition is provided to show excellent anti-oxidation capability, cell activation capability through cell proliferation, collagen synthesis promoting effect and immunity enhancing function within a short period of time without skin irritation and maintain the anti-aging effect for a long time. An anti-aging cosmetic composition comprises a fermented extract of oriental herb medicines obtained by adding the oriental herb medicines during culturing of yeast, lactic acid bacteria such as Lactobacillus sp. and Bacillus sp. or bacteria and then culturing it, wherein the oriental herb medicines is a mixture of ginseng, Radix Rehmanniae and Poria cocos in a weight ratio of 0.5-12:4-100:3-200, the yeast is at least one selected from the group consisting of Saccharomyces sp., Schizosaccharomyces sp. and Kluyveromyces sp., the lactic acid bacteria is at least one selected from the group consisting of Lactobacillus sp. and Bacillus sp., and the bacteria is at least one selected from the group consisting of Weissella sp., Gluconobacter sp. and Bacillus sp..
PURPOSE:To obtain an artificial erythrocyte having increased quantity of carried oxygen without requiring consideration of blood type in blood transfusion, by incorporating a hemoglobin solution containing an allosteric factor dissolved therein into a liposome. CONSTITUTION:An artificial erythrocyte obtained by adding inositol hexaphosphate which is one of allosteric factors to a hemoglobin solution free of erythrocytic membrane and converting the inositol hexaphosphate into a liposome. The concentration of the hemoglobin solution is preferably 30-60% (wt./wt.) and liposome membrane preferably consists essentially of hydrogenated phospholipid with >=50% hydrogenation ratio. The inositol hexaphosphate is used at 0.8-2 molar ratio based on the hemoglobin. Since the inositol hexaphosphate will not pass through the liposome membrane, the concentration of the inositol hexaphosphate based on the hemoglobin is kept at a constant value to enhance oxygen releasing ability.
Patients will receive initial dose of 0,05 mg/kg BID oftacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of sirolimus of 3mg once a day to reach blood trough concentration between 4-8 ng/mL.
FOSAMAX PLUS D alone should not be used to treat vitamin D deficiency.

The optimal duration of use has not been determined. The safety and effectiveness of FOSAMAX PLUS D for the treatment of osteoporosis are based on clinical data of four years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.
Vulvar lichen sclerosus (LS) is an inflammatory dermatosis that can progress to human papillomavirus (HPV)-independent vulvar intraepithelial neoplasia (HPVi VIN) and vulvar squamous cell carcinoma (VSCC). Although LS has a much lower cancer risk compared with HPVi VIN (5% vs 50%, respectively), its incidence is significantly higher. Therefore, there is a clinical need to identify LS patients with an increased cancer risk. Our objective was to study the value of DNA methylation and p53 immunohistochemistry (IHC) as prognostic biomarkers for progression to cancer in patients with LS. Vulvar tissues from 236 patients were selected, including 75 LS and 68 HPVi VIN, both with and without cancer development, 32 VSCC, and 61 healthy vulvar controls. Samples were subjected to p53 IHC and DNA methylation analysis of a 3-gene marker panel containing ZNF582, SST, and miR124-2. Methylation levels and p53 IHC status (mutant or wild-type) were assessed and compared among all disease categories. Odds ratios were determined to identify whether the biomarkers were associated with progression to cancer in patients with LS. The highest methylation levels were found in HPVi VIN and VSCC, followed by LS and healthy vulvar controls. The largest heterogeneity in methylation levels was observed in LS cases. In fact, the 3-marker panel tested positive in 70% of LS, which progressed to VSCC vs only 17% of LS in patients without cancer development (P = .002). Also, mutant p53 IHC was observed more frequently in LS with progression to VSCC compared with nonprogressive LS cases (42% vs 3%, respectively, P = .001). Multivariable analysis identified a mutant p53 status as the only independent risk factor for cancer development in LS (odds ratio: 34.0, 95% CI: 1.4-807.4). In conclusion, DNA methylation testing and p53 IHC show strong potential as prognostic biomarkers for the identification of LS patients at high risk of progression to cancer.
Methylmercury (MeHg) is a global environmental pollutant with neurotoxicity, which can easily crosses the blood-brain barrier and cause irreversible damage to the human central nervous system (CNS). CNS inflammation and autophagy are known to be involved in the pathology of neurodegenerative diseases. Meanwhile, MeHg has the potential to induce microglia-mediated neuroinflammation as well as autophagy. This study aims to further explore the exact molecular mechanism of MeHg neurotoxicity. We conducted in vitro studies using BV2 microglial cell from the central nervous system of mice. The role of inflammation and autophagy in the damage of BV2 cells induced by MeHg was determined by detecting cell viability, cell morphology and structure, reactive oxygen species (ROS), antioxidant function, inflammatory factors, autophagosomes, inflammation and autophagy-related proteins. We further investigated the relationship between the inflammatory response and autophagy induced by MeHg by inhibiting them separately. The results indicated that MeHg could invade cells, change cell structure, activate NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome and autophagosome, release a large amount of inflammatory factors and trigger the inflammatory response and autophagy. It was also found that MeHg could disrupt the antioxidant function of cells. In addition, the inhibition of NLRP3 inflammasome alleviated both cellular inflammation and autophagy, while inhibition of autophagy increased cellular inflammation. Our current research suggests that MeHg might induce BV2 cytotoxicity through inflammatory response and autophagy, which may be mediated by the NLRP3 inflammasome activated by oxidative stress.
Advanced pancreatic ductal adenocarcinoma (PDAC) is an aggressive and chemo-resistant disease with extremely low 5-year survival rate. Gemcitabine has been the cornerstone of metastatic PDAC treatment for more than a decade , although survival benefit was very poor. Nab-paclitaxel added to gemcitabine has showed improving survival and overall response rate vs gemcitabine alone in metastatic PDAC first-line treatment in the MPACT phaseIII study, which represents one of the standards of care in advanced PDAC therapy. S-1 is an oral 5-fluorouracil (5-FU) prodrug, and shown to be non-inferior to gemcitabine on OS for unresectable pancreatic cancer. Meanwhile, adjuvant chemotherapy with S-1 monotherapy was found to significant prolong survival of pancreatic cancer patients when compared with gemcitabine. This study is to explore the efficacy and safety of nab-paclitaxel plus S-1(AS) and nab-paclitaxel plus gemcitabine(AG) as first-line treatment in advanced pancreatic ductal adenocarcinoma (PDA) with primary tumor nonexcision in Chinese patients.